<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001646</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-BS-001</org_study_id>
    <nct_id>NCT05001646</nct_id>
  </id_info>
  <brief_title>Electromagnetic Field Protection Device Use Impact in Healthy Volunteers</brief_title>
  <official_title>Clinical and Molecular Impact of In-home Resonance-based Electromagnetic Field Protection Device Usage in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TruDiagnostic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blushield USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TruDiagnostic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single group, self-controlled study to evaluate the clinical and&#xD;
      molecular impact of continuous in-home resonance-based electromagnetic field (EMF) protection&#xD;
      device usage in healthy individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epigenetic Testing</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Aging</condition>
  <condition>Aging Well</condition>
  <arm_group>
    <arm_group_label>In-home EMF protection device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>In-home resonance-based electromagnetic field protection device</intervention_name>
    <description>Participants will have an in-home EMF protection device</description>
    <arm_group_label>In-home EMF protection device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any sex, gender orientation, and ethnicity&#xD;
&#xD;
          -  Between ages 30 and 70&#xD;
&#xD;
          -  Must be willing and able to participate in venipuncture, health history and clinical&#xD;
             assessments, passive monitoring (Oura ring), and continuous in-home Blushield device&#xD;
             usage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant change in diagnosis and/or treatment of major illness or injury within 2&#xD;
             years prior to screening, e.g., diabetes, cancer, cardiovascular disease, psychiatric&#xD;
             condition 2. Any ongoing immune system concerns or immunodeficiency disease&#xD;
&#xD;
          -  History of any viral illness in preceding year&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 35 kg/m2&#xD;
&#xD;
          -  Presence of active infection&#xD;
&#xD;
          -  Any other illness, disorder, alcohol or chemical dependence that in the opinion of&#xD;
             investigators would render study participation unsuitable&#xD;
&#xD;
          -  Unable or unwilling to provide required biological sample&#xD;
&#xD;
          -  Unable or unwilling to avoid pregnancy during study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natalie Amalani</last_name>
    <phone>816-377-4651</phone>
    <email>natalie@blushield-us.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annie Prestrud</last_name>
    <email>annie@trudiagnostic.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of Cellular Senescence. Trends Cell Biol. 2018 Jun;28(6):436-453. doi: 10.1016/j.tcb.2018.02.001. Epub 2018 Feb 21. Review.</citation>
    <PMID>29477613</PMID>
  </reference>
  <reference>
    <citation>Karipidis K, Mate R, Urban D, Tinker R, Wood A. 5G mobile networks and health-a state-of-the-science review of the research into low-level RF fields above 6 GHz. J Expo Sci Environ Epidemiol. 2021 Jul;31(4):585-605. doi: 10.1038/s41370-021-00297-6. Epub 2021 Mar 16. Review.</citation>
    <PMID>33727687</PMID>
  </reference>
  <reference>
    <citation>Kohli J, Wang B, Brandenburg SM, Basisty N, Evangelou K, Varela-Eirin M, Campisi J, Schilling B, Gorgoulis V, Demaria M. Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat Protoc. 2021 May;16(5):2471-2498. doi: 10.1038/s41596-021-00505-5. Epub 2021 Apr 28.</citation>
    <PMID>33911261</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

